{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:44:31Z","timestamp":1789901071874,"version":"4.0.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Waldenstr\u00f6m macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenstr\u00f6m macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Recent introduction of MYD88 mutational analysis has been very useful for diagnostic purposes but is unclear what effect it might have on the prognosis or response rate to therapy. An algorithm is provided on the management of asymptomatic individuals and the sequence used for chemotherapeutic intervention of symptomatic patients.<\/jats:p>","DOI":"10.1038\/s41408-018-0076-5","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T14:33:41Z","timestamp":1524666821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Waldenstr\u00f6m macroglobulinemia treatment algorithm 2018"],"prefix":"10.1038","volume":"8","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,1]]},"reference":[{"key":"76_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3816\/CLML.2011.n.011","volume":"11","author":"RA Kyle","year":"2011","unstructured":"Kyle, R. A. et al. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom\u2019s macroglobulinemia (SWM). Clin. Lymphoma Myeloma Leuk. 11, 74\u201376 (2011).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"76_CR2","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1182\/blood-2015-01-622068","volume":"125","author":"V Steingrimsson","year":"2015","unstructured":"Steingrimsson, V. et al. Population-based study on the impact of the familial form of Waldenstrom macroglobulinemia on overall survival. Blood 125, 2174\u20132175 (2015).","journal-title":"Blood"},{"key":"76_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bjh.13264","volume":"169","author":"JJ Castillo","year":"2015","unstructured":"Castillo, J. J. et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br. J. Haematol. 169, 81\u201389 (2015).","journal-title":"Br. J. Haematol."},{"key":"76_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen, R. G. et al. Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s macroglobulinemia. Semin. Oncol. 30, 110\u2013115 (2003).","journal-title":"Semin. Oncol."},{"key":"76_CR5","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","volume":"119","author":"RA Kyle","year":"2012","unstructured":"Kyle, R. A. et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 119, 4462\u20134466 (2012).","journal-title":"Blood"},{"key":"76_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E., Magen, H. & Gertz, M. A. How I treat cryoglobulinemia. Blood 129, 289\u2013298 (2017).","journal-title":"Blood"},{"key":"76_CR7","doi-asserted-by":"publisher","unstructured":"Berentsen S. How I manage patients with cold agglutinin disease. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.15109. 2018, PMID29363757.","DOI":"10.1111\/bjh.15109"},{"key":"76_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11940-017-0479-9","volume":"19","author":"E Nobile-Orazio","year":"2017","unstructured":"Nobile-Orazio, E., Bianco, M. & Nozza, A. Advances in the treatment of paraproteinemic neuropathy. Curr. Treat. Options Neurol. 19, 43 (2017).","journal-title":"Curr. Treat. Options Neurol."},{"key":"76_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/00207454.2016.1191013","volume":"127","author":"G Galassi","year":"2017","unstructured":"Galassi, G. et al. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int. J. Neurosci. 127, 439\u2013447 (2017).","journal-title":"Int. J. Neurosci."},{"key":"76_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.beha.2016.08.013","volume":"29","author":"P Milani","year":"2016","unstructured":"Milani, P. & Merlini, G. Monoclonal IgM-related AL amyloidosis. Best. Pract. Res. Clin. Haematol. 29, 241\u2013248 (2016).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"76_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jns.2010.06.023","volume":"297","author":"Y Kawano","year":"2010","unstructured":"Kawano, Y. et al. Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. J. Neurol. Sci. 297, 101\u2013104 (2010).","journal-title":"J. Neurol. Sci."},{"key":"76_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00277-017-2968-z","volume":"96","author":"XX Cao","year":"2017","unstructured":"Cao, X. X. et al. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann. Hematol. 96, 971\u2013976 (2017).","journal-title":"Ann. Hematol."},{"key":"76_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24955","volume":"93","author":"JP Abeykoon","year":"2018","unstructured":"Abeykoon, J. P. et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am. J. Hematol. 93, 187\u2013194 (2018).","journal-title":"Am. J. Hematol."},{"key":"76_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bjh.15049","volume":"180","author":"SP Treon","year":"2018","unstructured":"Treon, S. P. et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br. J. Haematol. 180, 374\u2013380 (2018).","journal-title":"Br. J. Haematol."},{"key":"76_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3109\/10428194.2014.924123","volume":"56","author":"N Patkar","year":"2015","unstructured":"Patkar, N. et al. MYD88 mutant lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leuk. Lymphoma 56, 420\u2013425 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"76_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/leu.2013.62","volume":"27","author":"C Jimenez","year":"2013","unstructured":"Jimenez, C. et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom\u2019s macroglobulinemia. Leukemia 27, 1722\u20131728 (2013).","journal-title":"Leukemia"},{"key":"76_CR17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.leukres.2010.04.005","volume":"34","author":"E Kastritis","year":"2010","unstructured":"Kastritis, E. et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom\u2019s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk. Res. 34, 1340\u20131343 (2010).","journal-title":"Leuk. Res."},{"key":"76_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.leukres.2016.05.002","volume":"46","author":"XX Cao","year":"2016","unstructured":"Cao, X. X. et al. The clinical spectrum of IgM monoclonal gammopathy: a single center retrospective study of 377 patients. Leuk. Res. 46, 85\u201388 (2016).","journal-title":"Leuk. Res."},{"key":"76_CR20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","volume":"34","author":"S Sachchithanantham","year":"2016","unstructured":"Sachchithanantham, S. et al. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m-related light chain amyloidosis. J. Clin. Oncol. 34, 2037\u20132045 (2016).","journal-title":"J. Clin. Oncol."},{"key":"76_CR21","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","volume":"122","author":"PL Swiecicki","year":"2013","unstructured":"Swiecicki, P. L., Hegerova, L. T. & Gertz, M. A. Cold agglutinin disease. Blood 122, 1114\u20131121 (2013).","journal-title":"Blood"},{"issue":"Suppl 103(1)","key":"76_CR22","first-page":"67","volume":"35","author":"M Galli","year":"2017","unstructured":"Galli, M. et al. HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Clin. Exp. Rheumatol. 35(Suppl 103(1)), 67\u201376 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"76_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.dld.2016.03.018","volume":"48","author":"C Mazzaro","year":"2016","unstructured":"Mazzaro, C. et al. Hepatitis B virus related cryoglobulinemic vasculitis: a multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie\u2013GISC. Dig. Liver. Dis. 48, 780\u2013784 (2016).","journal-title":"Dig. Liver. Dis."},{"key":"76_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","volume":"10","author":"K Gill","year":"2016","unstructured":"Gill, K., Ghazinian, H., Manch, R. & Gish, R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol. Int. 10, 415\u2013423 (2016).","journal-title":"Hepatol. Int."},{"key":"76_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.hoc.2017.09.010","volume":"32","author":"A Dispenzieri","year":"2018","unstructured":"Dispenzieri, A., Kourelis, T. & Buadi, F. POEMS syndrome: diagnosis and investigative work-up. Hematol. Oncol. Clin. North. Am. 32, 119\u2013139 (2018).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"issue":"Suppl 2","key":"76_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10072-017-3024-4","volume":"38","author":"D Franciotta","year":"2017","unstructured":"Franciotta, D. et al. Diagnostics of anti-MAG antibody polyneuropathy. Neurol. Sci. 38(Suppl 2), 249\u2013252 (2017).","journal-title":"Neurol. Sci."},{"key":"76_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjh.14492","volume":"176","author":"S D\u2019Sa","year":"2017","unstructured":"D\u2019Sa, S. et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br. J. Haematol. 176, 728\u2013742 (2017).","journal-title":"Br. J. Haematol."},{"key":"76_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2141.2009.07892.x","volume":"147","author":"MA Gertz","year":"2009","unstructured":"Gertz, M. A. et al. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br. J. Haematol. 147, 677\u2013680 (2009).","journal-title":"Br. J. Haematol."},{"issue":"5 Peripheral Ne","key":"76_CR29","first-page":"1307","volume":"20","author":"ML Mauermann","year":"2014","unstructured":"Mauermann, M. L. Paraproteinemic neuropathies. Contin. (Minneap. Minn.). 20 (5 Peripheral Nervous System Disorders), 1307\u20131322 (2014).","journal-title":"Contin. (Minneap. Minn.)."},{"key":"76_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","volume":"14","author":"Q Reynaud","year":"2015","unstructured":"Reynaud, Q. et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun. Rev. 14, 304\u2013313 (2015).","journal-title":"Autoimmun. Rev."},{"key":"76_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000445841","volume":"43","author":"D Roccatello","year":"2016","unstructured":"Roccatello, D. et al. Improved (4 plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am. J. Nephrol. 43, 251\u2013260 (2016).","journal-title":"Am. J. Nephrol."},{"key":"76_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bjh.14881","volume":"179","author":"E Durot","year":"2017","unstructured":"Durot, E. et al. Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br. J. Haematol. 179, 439\u2013448 (2017).","journal-title":"Br. J. Haematol."},{"key":"76_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/10428194.2016.1217527","volume":"58","author":"JJ Castillo","year":"2017","unstructured":"Castillo, J. J. & Gertz, M. A. Secondary malignancies in patients with multiple myeloma, Waldenstrom macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk. Lymphoma 58, 773\u2013780 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"76_CR34","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2011.031","volume":"3","author":"F Ricci","year":"2011","unstructured":"Ricci, F., Tedeschi, A., Montillo, M. & Morra, E. Therapy-related myeloid neoplasms in chronic lymphocytic leukemia and Waldenstrom\u2019s macroglobulinemia. Mediterr. J. Hematol. Infect. Dis. 3, e2011031 (2011).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"76_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.06.004","volume":"105","author":"A Santos-Lozano","year":"2016","unstructured":"Santos-Lozano, A. et al. Response rate to the treatment of Waldenstrom macroglobulinemia: a meta-analysis of the results of clinical trials. Crit. Rev. Oncol. Hematol. 105, 118\u2013126 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"76_CR36","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","volume":"3","author":"P Kapoor","year":"2017","unstructured":"Kapoor, P. et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo Stratification Of Macroglobulinemia and Risk-adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 3, 1257\u20131265 (2017).","journal-title":"JAMA Oncol."},{"key":"76_CR37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","volume":"55","author":"HC Kwaan","year":"2013","unstructured":"Kwaan, H. C. Hyperviscosity in plasma cell dyscrasias. Clin. Hemorheol. Microcirc. 55, 75\u201383 (2013).","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"76_CR38","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2011-04-347690","volume":"119","author":"MJ Stone","year":"2012","unstructured":"Stone, M. J. & Bogen, S. A. Evidence-based focused review of management of hyperviscosity syndrome. Blood 119, 2205\u20132208 (2012).","journal-title":"Blood"},{"key":"76_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3816\/CLM.2009.n.019","volume":"9","author":"C Chen","year":"2009","unstructured":"Chen, C. et al. Bortezomib in relapsed or refractory Waldenstrom\u2019s macroglobulinemia. Clin. Lymphoma Myeloma 9, 74\u201376 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"76_CR40","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","volume":"126","author":"E Kastritis","year":"2015","unstructured":"Kastritis, E. et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood 126, 1392\u20131394 (2015).","journal-title":"Blood"},{"key":"76_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","volume":"31","author":"V Leblond","year":"2013","unstructured":"Leblond, V. et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J. Clin. Oncol. 31, 301\u2013307 (2013).","journal-title":"J. Clin. Oncol."},{"key":"76_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cncr.26303","volume":"118","author":"A Tedeschi","year":"2012","unstructured":"Tedeschi, A. et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118, 434\u2013443 (2012).","journal-title":"Cancer"},{"key":"76_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clml.2013.02.011","volume":"13","author":"A Tedeschi","year":"2013","unstructured":"Tedeschi, A. et al. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenstrom\u2019s macroglobulinemia. Clin. Lymphoma Myeloma Leuk. 13, 231\u2013234 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"76_CR44","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ajh.24405","volume":"91","author":"L Souchet","year":"2016","unstructured":"Souchet, L. et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom\u2019s macroglobulinemia. Am. J. Hematol. 91, 782\u2013786 (2016).","journal-title":"Am. J. Hematol."},{"key":"76_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3816\/CLML.2011.n.029","volume":"11","author":"D Laszlo","year":"2011","unstructured":"Laszlo, D. et al. Rituximab and subcutaneous 2-chloro-2\u2019-deoxyadenosine as therapy in untreated and relapsed Waldenstrom\u2019s macroglobulinemia. Clin. Lymphoma Myeloma Leuk. 11, 130\u2013132 (2011).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"76_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/10428194.2014.911869","volume":"56","author":"I Herth","year":"2015","unstructured":"Herth, I. et al. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenstrom\u2019s macroglobulinemia. Leuk. Lymphoma 56, 97\u2013102 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"76_CR47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","volume":"129","author":"M Gavriatopoulou","year":"2017","unstructured":"Gavriatopoulou, M. et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 129, 456\u2013459 (2017).","journal-title":"Blood"},{"key":"76_CR48","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon, S. P. et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J. Clin. Oncol. 27, 3830\u20133835 (2009).","journal-title":"J. Clin. Oncol."},{"key":"76_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","volume":"17","author":"K Viala","year":"2012","unstructured":"Viala, K. et al. Heterogeneous spectrum of neuropathies in Waldenstrom\u2019s macroglobulinemia: a diagnostic strategy to optimize their management. J. Peripher. Nerv. Syst. 17, 90\u2013101 (2012).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"76_CR50","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/blood-2017-08-798512","volume":"130","author":"JJ Castillo","year":"2017","unstructured":"Castillo, J. J. et al. Bendamustine and bortezomib-containing regimens produce higher response rates and more durable responses versus cyclophosphamide-based therapy in frontline Waldenstrom macroglobulinemia. Blood 130, 1488 (2017).","journal-title":"Blood"},{"key":"76_CR51","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1002\/ajh.23985","volume":"90","author":"H Leblebjian","year":"2015","unstructured":"Leblebjian, H. et al. Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenstrom macroglobulinemia. Am. J. Hematol. 90, E122\u2013E123 (2015).","journal-title":"Am. J. Hematol."},{"key":"76_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12185-014-1705-9","volume":"101","author":"Y Kikukawa","year":"2015","unstructured":"Kikukawa, Y. et al. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Int. J. Hematol. 101, 133\u2013139 (2015).","journal-title":"Int. J. Hematol."},{"key":"76_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"SP Treon","year":"2014","unstructured":"Treon, S. P. et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom\u2019s macroglobulinemia. Blood 124, 503\u2013505 (2014).","journal-title":"Blood"},{"key":"76_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/10428194.2017.1321749","volume":"59","author":"DH Vesole","year":"2018","unstructured":"Vesole, D. H. et al. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leuk. Lymphoma 59, 259\u2013261 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"76_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ajh.23620","volume":"89","author":"IM Ghobrial","year":"2014","unstructured":"Ghobrial, I. M. et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am. J. Hematol. 89, 237\u2013242 (2014).","journal-title":"Am. J. Hematol."},{"key":"76_CR56","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/leu.2015.164","volume":"29","author":"IM Ghobrial","year":"2015","unstructured":"Ghobrial, I. M. et al. Phase I\/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed\/refractory Waldenstrom macroglobulinemia. Leukemia 29, 2338\u20132346 (2015).","journal-title":"Leukemia"},{"key":"76_CR57","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/bmt.2014.113","volume":"49","author":"MA Marzolini","year":"2014","unstructured":"Marzolini, M. A., Thomson, K. J., Dorman, J. & D\u2019Sa, S. BEAM-conditioned autologous SCT improves the quality of response in Waldenstrom\u2019s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre\u2019s 10-year experience. Bone Marrow Transplant. 49, 1231\u20131232 (2014).","journal-title":"Bone Marrow Transplant."},{"key":"76_CR58","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel, M. J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381, 1203\u20131210 (2013).","journal-title":"Lancet"},{"key":"76_CR59","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","volume":"56","author":"A Tedeschi","year":"2015","unstructured":"Tedeschi, A. et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk. Lymphoma 56, 2637\u20132642 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"76_CR60","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.24175","volume":"90","author":"G Fouquet","year":"2015","unstructured":"Fouquet, G. et al. Lenalidomide is safe and active in Waldenstrom macroglobulinemia. Am. J. Hematol. 90, 1055\u20131059 (2015).","journal-title":"Am. J. Hematol."},{"key":"76_CR61","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","volume":"15","author":"SP Treon","year":"2009","unstructured":"Treon, S. P. et al. Lenalidomide and rituximab in Waldenstrom\u2019s macroglobulinemia. Clin. Cancer Res. 15, 355\u2013360 (2009).","journal-title":"Clin. Cancer Res."},{"key":"76_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos, M. A. et al. Update on treatment recommendations from the fourth international workshop on Waldenstrom\u2019s macroglobulinemia. J. Clin. Oncol. 27, 120\u2013126 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"Spec Feature","key":"76_CR63","first-page":"89","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler, L. A. Imbruvica (Ibrutinib): first drug approved for the treatment of patients with Waldenstrom\u2019s macroglobulinemia. Am. Health Drug Benefits 9 (Spec Feature), 89\u201392 (2016).","journal-title":"Am. Health Drug Benefits"},{"key":"76_CR64","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"76_CR65","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ajh.25023","volume":"93","author":"JN Gustine","year":"2017","unstructured":"Gustine, J. N. et al. Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. Am. J. Hematol. 93, 511\u2013517 (2017).","journal-title":"Am. J. Hematol."},{"key":"76_CR66","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain, P. et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125, 2062\u20132067 (2015).","journal-title":"Blood"},{"key":"76_CR67","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","volume":"102","author":"I de Weerdt","year":"2017","unstructured":"de Weerdt, I., Koopmans, S. M., Kater, A. P. & van Gelder, M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 102, 1629\u20131639 (2017).","journal-title":"Haematologica"},{"key":"76_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","volume":"17","author":"S Yun","year":"2017","unstructured":"Yun, S., Vincelette, N. D., Acharya, U. & Abraham, I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin. Lymphoma Myeloma Leuk. 17, 31\u201337 (2017). e13.","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"76_CR69","doi-asserted-by":"publisher","first-page":"E312","DOI":"10.1002\/ajh.24366","volume":"91","author":"JN Gustine","year":"2016","unstructured":"Gustine, J. N., Meid, K., Dubeau, T. E., Treon, S. P. & Castillo, J. J. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am. J. Hematol. 91, E312\u2013E313 (2016).","journal-title":"Am. J. Hematol."},{"key":"76_CR70","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Ibrutinib for patients with rituximab-refractory Waldenstrom\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 18, 241\u2013250 (2017).","journal-title":"Lancet Oncol."},{"key":"76_CR71","first-page":"2767","volume":"130","author":"SP Treon","year":"2017","unstructured":"Treon, S. P. et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom\u2019s macroglobulinemia. Blood 130, 2767 (2017).","journal-title":"Blood"},{"key":"76_CR72","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"76_CR73","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1080\/10428194.2016.1222380","volume":"58","author":"JJ Castillo","year":"2017","unstructured":"Castillo, J. J. et al. Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity. Leuk. Lymphoma 58, 1002\u20131004 (2017).","journal-title":"Leuk. Lymphoma"}],"updated-by":[{"DOI":"10.1038\/s41408-019-0212-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0076-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0076-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0076-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:34:44Z","timestamp":1671536084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0076-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0076-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]},"assertion":[{"value":"15 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Gertz reports personal fees from Ionis, Alnylym, Prothena, Celgene, Janssen, Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, Abbvie, Research to Practice, Teva, and grants and personal fees from Spectrum, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"40"}}